B. Riley Financial Varied
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

0.6060 -0.0038 (-0.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 243,145
Open 0.6000
Bid (Size) 0.6060 (34)
Ask (Size) 0.6300 (5)
Prev. Close 0.6098
Today's Range 0.6000 - 0.6283
52wk Range 0.5606 - 124.88
Shares Outstanding 3,246,284
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga

Performance

YTD
-99.3%
-99.3%
1 Month
-51.9%
-51.9%
3 Month
-49.9%
-49.9%
6 Month
-56.4%
-56.4%
1 Year
-99.4%
-99.4%

More News

Read More
Which stocks are experiencing notable movement on Wednesday?
Via Chartmill
Wednesday's session: gap up and gap down stocks
Via Chartmill
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Participation in 2025 BIO International Convention
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Participating in BIO-Europe Spring®
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
From Enveric Biosciences
Via Business Wire

Frequently Asked Questions

Is Enveric Biosciences, Inc. - Common Stock publicly traded?
Yes, Enveric Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Enveric Biosciences, Inc. - Common Stock trade on?
Enveric Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Enveric Biosciences, Inc. - Common Stock?
The ticker symbol for Enveric Biosciences, Inc. - Common Stock is ENVB on the Nasdaq Stock Market
What is the current price of Enveric Biosciences, Inc. - Common Stock?
The current price of Enveric Biosciences, Inc. - Common Stock is 0.6060
When was Enveric Biosciences, Inc. - Common Stock last traded?
The last trade of Enveric Biosciences, Inc. - Common Stock was at 09/26/25 04:00 PM ET
What is the market capitalization of Enveric Biosciences, Inc. - Common Stock?
The market capitalization of Enveric Biosciences, Inc. - Common Stock is 1.97M
How many shares of Enveric Biosciences, Inc. - Common Stock are outstanding?
Enveric Biosciences, Inc. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.